Previous 10 | Next 10 |
Atea Pharmaceuticals (AVIR): FY GAAP EPS of -$0.51 beats by $0.94.Revenue of $48.63MPress Release For further details see: Atea Pharmaceuticals EPS beats by $0.94
– Rapid advancement of AT-527 for COVID-19 – – Strategic collaboration with Roche to develop and commercialize AT-527 for COVID-19 – – Initiation of Phase 1a trial of AT-752 for dengue fever – – Crossover financing...
BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial ...
Atea Pharmaceuticals (AVIR) presents results from the Phase 1 study of AT-527 in 20 healthy volunteers, randomized 1:1 to receive oral AT-527 550 mg twice daily ((BID)) or matching placebo for 5 days.The purpose of this study was to assess the safety and pharmacokinetics ((PK)) of AT-527 and ...
High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients Data Supportive of AT-527 550 mg BID Dosing Regimen BOSTON, March 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharm...
Chugai Pharmaceutical (CHGCF) has in-licensed the rights for Atea Pharmaceuticals' (AVIR) AT-527 for the treatment of COVID-19 in Japan from Roche (RHHBY).Roche and Atea are jointly developing AT-527 for COVID-19 and Roche has the right to commercialize AT-527 outside U.S. The compa...
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has in-licensed the rights for AT-527 for the treatment of COVID-19 in J...
Atea Pharmaceuticals (AVIR) announced the publication of new data indicating the in vitro antiviral activity of AT-527 against SARS-CoV-2.With AT-527 activated in cultured normal human nasal and bronchial epithelial cells, AT-511, the freebase of AT-527, has shown a highly...
BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT...
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...